IN8bio, Inc. (NASDAQ:INAB – Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 45,907 shares, a drop of 57.3% from the May 31st total of 107,416 shares. Based on an average trading volume of 55,764 shares, the short-interest ratio is currently 0.8 days. Approximately 0.5% of the shares of the stock are short sold.
Institutional Trading of IN8bio
Institutional investors have recently made changes to their positions in the stock. 683 Capital Management LLC purchased a new position in shares of IN8bio in the fourth quarter worth $1,696,000. Captrust Financial Advisors purchased a new position in shares of IN8bio in the 4th quarter worth $43,000. Alyeska Investment Group L.P. raised its position in IN8bio by 1,060.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after purchasing an additional 875,000 shares during the period. HRT Financial LP bought a new stake in shares of IN8bio in the 4th quarter valued at approximately $34,000. Finally, Franklin Resources Inc. lifted its stake in shares of IN8bio by 381.6% in the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock valued at $2,048,000 after purchasing an additional 724,637 shares during the last quarter. Hedge funds and other institutional investors own 92.05% of the company’s stock.
IN8bio Stock Up 5.5%
Shares of NASDAQ INAB traded up $0.07 on Monday, reaching $1.44. 48,236 shares of the company’s stock traded hands, compared to its average volume of 68,076. IN8bio has a 12 month low of $1.17 and a 12 month high of $2.73. The business’s 50 day simple moving average is $1.53 and its two-hundred day simple moving average is $1.74. The company has a market cap of $14.13 million, a price-to-earnings ratio of -0.55 and a beta of 0.19.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on INAB shares. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.00.
Check Out Our Latest Report on INAB
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.
See Also
- Five stocks we like better than IN8bio
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
